Natera (NTRA) news
Recent news
ABSA names NCBA's Muriuiki to role in personal banking unit: BD
AInvest Wire · 17h agoNatera & Transcode Therapeutics collaborate on CRC
Natera, Inc. (NASDAQ: NTRA) has announced a collaboration with Transcode Therapeutics to advance research and development in the detection and treatment of colorectal cancer (CRC). The partnership aims to leverage Natera’s expertise in genomic analysis and Transcode’s innovative therapeutic…
AInvest Wire · 1d agoNatera - Transcode to use Signatera test to identify mrd-positive patients for enrollment
AInvest Wire · 1d agoNatera and Transcode Therapeutics to collaborate on phase 2A trial of TTX-MC138 in colorectal cancer
Natera, Inc. (NASDAQ: NTRA) and Transcode Therapeutics have announced a collaboration to conduct a phase 2A clinical trial of TTX-MC138, an investigational therapy targeting colorectal cancer. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of TTX-MC138 in patients…
AInvest Wire · 1d agoNatera, Inc.: TD Cowen raises target price to $480 from $340
TD Cowen has raised its price target for Natera, Inc. (NASDAQ: NTRA) to $480 from $340, reflecting a significant increase in analyst optimism regarding the company’s future performance. Natera, a leader in cell-free DNA (cfDNA) and genetic testing, operates across oncology, women’s health, and…
AInvest Wire · 1d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.